Abstract:
This programme aimed at consolidating and sustaining the capacity building that European partners have invested in HIV vaccine trial
preparations in Tanzania, and at the same time to expand a South-South capacity building effort in Mozambique. This has been achieved, and
three centres in these countries have been prepared to take part in future phase II/III HIV vaccine studies. The successful completion of a DNA
prime modified Vaccinia Ankara (MVA) boost vaccine trial that enrolled 120 participants, and the successful administration of a further
adjuvanted protein (rgp 140/GLA) boost, in 40 participants in Dar es Salaam and Mbeya, is testimony to the capacity in Tanzania. In
Mozambique, investigators have now completed a DNA prime/MVA boost trial in 24 youths. All three centres are ready to embark on the next
multi-centre trial. The results from the main Tanzanian trial (TMV-01) have been presented at the AIDS Vaccine Conference 2012 in Boston,
and are being summarised in a series of manuscripts. Evaluation of cellular and humoral responses following the protein boost in Tanzania, and
the Mozambique immune responses are ongoing.
